Bladder Cancer Treatment Outcomes: New Study Finds Gem/doce Therapy More Effective Than Additional BCG in BCG-Unresponsive Patients

Strategic Insights -

Researchers from the University of Texas Southwestern Medical Center have conducted a study comparing oncologic outcomes between sequential intravesical gemcitabine and docetaxel (gem/doce) versus additional bacillus Calmette-Guérin (BCG) in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The study, published in European Urology Oncology, aimed to determine which treatment is more effective in preventing progression and improving survival rates.

Key Takeaways:

  • The study involved 299 patients with BCG-unresponsive NMIBC, with 204 receiving additional BCG treatment and 95 receiving gem/doce therapy.
  • Patients receiving gem/doce therapy had higher rates of progression-free survival (HR 2.6, 95% CI 1.1-5.0, p = 0.03), cystectomy-free survival (HR 2.0, 95% CI 1.2-3.4, p = 0.01), and cancer-specific survival (HR 3.7, 95% CI 1.1-12.3, p=0.03) compared to those receiving additional BCG treatment.
  • However, there were no significant differences in high-grade recurrence-free survival, metastasis-free survival, and overall survival between the two groups.
  • The study's findings suggest that intravesical gem/doce therapy is associated with lower rates of progression than additional BCG treatment in patients with BCG-unresponsive NMIBC who decline or are ineligible for cystectomy.
  • The study's conclusions are based on data collected from ten academic institutions and have been peer-reviewed.

Statistics:

  • 299 patients were included in the study.
  • 204 patients received additional BCG treatment as part of the study.
  • 95 patients received gem/doce therapy as part of the study.
  • The study found a significant difference in progression-free survival (HR 2.6, 95% CI 1.1-5.0, p = 0.03) between the two groups.
  • The study also found a significant difference in cystectomy-free survival (HR 2.0, 95% CI 1.2-3.4, p = 0.01) and cancer-specific survival (HR 3.7, 95% CI 1.1-12.3, p=0.03) between the two groups.

Sources:

  • Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared With Bacillus Calmette-guerin In Patients With Bacillus Calmette-guerin-unresponsive Non-muscle Invasive Bladder Cancer. European Urology Oncology, 2025;8(2):469-476.
  • European Urology Oncology can be contacted at: Elsevier, Radarweg 29, 1043 Nx Amsterdam, Netherlands.
  • NewsRx. Studies from University of Texas Southwestern Medical Center Update Current Data on Bladder Cancer (Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared With Bacillus Calmette-guerin In Patients With Bacillus ...). Cancer Weekly. May 20, 2025; p 943.